Institute of Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium; Faculty of Medicine, Université catholique de Bukavu, Bukavu, Democratic Republic of Congo; General Pediatrics, Pediatric Department, Hôpital Provincial Général de Référence de Bukavu, Bukavu, Democratic Republic of Congo; Institut Supérieur des Techniques Médicales, Bukavu, Democratic Republic of Congo; Center for Tropical Diseases and Global Health, Université catholique de Bukavu, Bukavu, Democratic Republic of the Congo.
Faculty of Medicine, Université catholique de Bukavu, Bukavu, Democratic Republic of Congo; General Pediatrics, Pediatric Department, Hôpital Provincial Général de Référence de Bukavu, Bukavu, Democratic Republic of Congo.
Am J Clin Nutr. 2023 May;117(5):976-984. doi: 10.1016/j.ajcnut.2023.01.019. Epub 2023 Apr 19.
Severe acute malnutrition (SAM) contributes to nearly 1 million deaths annually worldwide, with diarrhea and pneumonia being the common morbidity associated with mortality.
To assess the effect of probiotics on diarrhea, pneumonia, and nutritional recovery in children with uncomplicated SAM.
A randomized, double-blind, placebo-controlled study was conducted involving 400 children with uncomplicated SAM randomly assigned to ready-to-use therapeutic food (RUTF) either with (n = 200) or without (n = 200) probiotics. Patients received 1 mL daily dose of a blend of Lacticasebacillus rhamnosus GG and Limosilactobacillus reuteri DSM 17938 (dosage, 2 billion colony-forming units; 50:50) or placebo during 1 mo. They were simultaneously fed with the RUTF for 6 to 12 wk, depending on patients' recovery rates. The primary outcome was the duration of diarrhea. Secondary outcomes included diarrheal and pneumonic incidence, nutritional recovery, and transfer to inpatient care rate.
For children with diarrhea, the number of days of disease was lower in the probiotic group (4.11; 95% CI: 3.37, 4.51) than that in the placebo group (6.68; 95% CI: 6.26, 7.13; P < 0.001). For children aged 16 mo or older, the risk of diarrhea was lower in the probiotic group (75.6%; 95% CI: 66.2, 82.9) than that in the placebo group (95.0%; 95% CI: 88.2, 97.9; P < 0.001), but no significant difference of the risk for the youngest. In the probiotic group, nutritional recovery happened earlier: at the 6th wk, 40.6% of the infants were waiting for nutritional recovery, contrasting with 68.7% of infants in the placebo group; but the nutritional recovery rate at the 12th wk was similar between the groups. Probiotics had no effect on pneumonic incidence and transfer to inpatient care.
This trial supports using probiotics for the treatment of children with uncomplicated SAM. Its effect on diarrhea could positively affect nutritional programs in resource-limited settings. This trial was registered https://pactr.samrc.ac.za as PACTR202108842939734.
严重急性营养不良(SAM)导致全球每年近 100 万人死亡,腹泻和肺炎是与死亡率相关的常见并发症。
评估益生菌对无并发症 SAM 儿童腹泻、肺炎和营养恢复的影响。
进行了一项随机、双盲、安慰剂对照研究,纳入 400 名无并发症 SAM 儿童,随机分配至接受即用型治疗食品(RUTF)的儿童中(n=200)或不接受益生菌(n=200)的儿童。患者接受每日 1 毫升含有鼠李糖乳杆菌 GG 和罗伊氏乳杆菌 DSM 17938 的混合物(剂量,20 亿菌落形成单位;50:50)或安慰剂治疗 1 个月。同时,根据患者的恢复速度,用 RUTF 喂养 6 至 12 周。主要结局为腹泻持续时间。次要结局包括腹泻和肺炎发生率、营养恢复和住院治疗率。
对于腹泻患儿,益生菌组的疾病天数(4.11;95%CI:3.37,4.51)低于安慰剂组(6.68;95%CI:6.26,7.13;P<0.001)。对于 16 个月或以上的儿童,益生菌组的腹泻风险低于安慰剂组(75.6%;95%CI:66.2,82.9),而最年轻的儿童无显著差异(95.0%;95%CI:88.2,97.9;P<0.001)。在益生菌组中,营养恢复更早发生:在第 6 周,有 40.6%的婴儿等待营养恢复,而安慰剂组中则有 68.7%的婴儿;但在第 12 周时,两组的营养恢复率相似。益生菌对肺炎发生率和住院治疗无影响。
本试验支持使用益生菌治疗无并发症 SAM 儿童。其对腹泻的影响可能会对资源有限环境中的营养计划产生积极影响。本试验在 PACTr 注册,https://pactr.samrc.ac.za,注册号为 PACTR202108842939734。